GLP-1 drugs — bone/gout/osteo risks + regain + menopause weight
Key Questions
What bone health risks come with GLP-1 drugs?
GLP-1 drugs can accelerate hip bone loss, especially in women without diabetes, due to rapid weight loss; a 30% increased osteoporosis or muscle risk occurs without adequate protein, resistance training, or creatine.
How effective is combining HRT with tirzepatide for weight loss?
A Mayo Clinic study found that HRT boosts tirzepatide weight loss by 35%, helping address menopause-related challenges like increased belly fat and cardiovascular risk.
Do GLP-1 drugs affect fracture or cancer risk?
Semaglutide is linked to a 15% lower fracture risk in type 2 diabetes, while GLP-1s overall are associated with a 41% lower risk of obesity-related cancers.
30% osteo/musc risk w/o prot/RT/creat; 70% regain; focus protein 1.2-1.5g/kg + fiber; menopause IMAT/CV/belly weight challenges. Mayo Clinic study shows HRT boosts tirzepatide weight loss by 35%. Semaglutide linked to 15% lower fracture risk in type 2 diabetes; GLP-1s linked to 41% lower obesity-related cancer risk. Accepted perspective on using deoxypyridinoline urine test to monitor bone loss during GLP-1 therapy. International Journal of Obesity treat-to-target approach reframes obesity pharmacotherapy. New this run: JCEM study shows GLP-1 drugs accelerate hip bone loss, especially in women without diabetes, driven by rapid weight loss—reinforces need for DXA, resistance training, protein, calcium.